( -------------------------- ------------...)Ascenta Therapeutics Highlights Multiple Data Presentations at,Upcoming AACR Annual Meeting,Health

-------------------------- -------------- Sunday 8am-12pm Synergistic inhibition of tumor Xiongwen Zhang April 15 growth by combined treatment with MD, PhD the pan Bcl-2 inhibitor AT-101 Ascenta and docetaxel in human cancer Therapeutics. xenograft models ---------------------------------- -------------- A novel small molecular inhibitor Jason Canner targets the MDM2-p53 interaction DO, Columbus significantly reducing cell Children's viability in both embryonal and Hospital alveolar rhabdomyosarcoma cells with wild-type p53 --------- ---------------------------------- -------------- 1pm-5pm AT-101-induced apoptosis in VCaP Robert Loberg androgen-sensitive cells is PhD inhibited by the presence of DHT U. Michigan ---------------------------------- -------------- Synergistic effect of AT-101, an Xiongwen orally active pan-Bcl-2 family Zhang, MD, protein inhibitor in combination PhD with dual-Raf/MEK and VEGFR Ascenta kinase inhibitor sorafenib Therapeutics (Nexavar(R)) --------- --------- ---------------------------------- -------------- Tuesday 3:30pm Preclinical characterization of Dajun Yang, April 17 MI-219, a novel potent oral small MD, PhD molecule inhibitor of the MDM2- Ascenta p53 interaction Therapeutics --------- ---------------------------------- -------------- 1pm-5pm Synergistic anti-tumor effect with Nathalie combinat
'"/>




Page: 1 2 3 4 5 6
Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care